Catalyst
Slingshot members are tracking this event:
Following approval recommendation from FDA Advisory Committee for CTL-019 in pediatric Acute lymphoblastic leukemia (ALL), Novartis to submit drug to Europe for approval by end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 06, 2017
Occurred Source:
https://www.novartis.com/news/media-releases/novartis-reaches-another-regulatory-milestone-ctl019-tisagenlecleucel-submission
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Recommendation For Approval, Ctl-019, Acute Lymphoblastic Leukemia, Ema Submission
